Physician profile
Travis Logan Larson
NPI 1417482373
$6,059.42
in general payments reported to CMS, 2019-2025
41 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $225 · 2021: $1,315 · 2022: $1,133 · 2023: $1,252 · 2024: $1,059 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $917.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $811.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $581.17 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $462.37 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $385.12 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $380.64 | 2021-2025 | |
| Amgen INC. | $346.92 | 2020-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $206.95 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.36 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $150.37 | 2020-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $130.45 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $117.09 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.33 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $104.08 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $100.07 | 2020-2025 | Belsomra, Januvia, Steglatro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.